JAK1 and hepatocellular carcinoma: Like the STAT6 inhibitor, the multi tyrosine kinase receptor inhibitor sunitinib suppressed M2 polarization of RAW264.7 murine macrophages and diminished JAK1-STAT6 signaling both in vitro and in vivo in mice, leading to dampening of the malignant behaviors of HCC cells (Kong and Guo, 2023).